+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
MDS - Pipeline Insight, 2024 - Product Thumbnail Image

MDS - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
HR-Positive-HER-negative - Pipeline Insight, 2024 - Product Thumbnail Image

HR-Positive-HER-negative - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
HPV-induced Cutaneous Tumors - Pipeline Insight, 2024 - Product Thumbnail Image

HPV-induced Cutaneous Tumors - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Gliosarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Gliosarcoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Adult R/R RAF-Altered Solid Tumors - Pipeline Insight, 2024 - Product Thumbnail Image

Adult R/R RAF-Altered Solid Tumors - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
Metastatic Head and Neck Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Head and Neck Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Multiple myeloma-related bone disease - Pipeline Insight, 2024 - Product Thumbnail Image

Multiple myeloma-related bone disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Natural Killer (NK)-Cell Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Natural Killer (NK)-Cell Lymphoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 100 Pages
  • Global
From
PTCL-NOS - Pipeline Insight, 2024 - Product Thumbnail Image

PTCL-NOS - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024 - Product Thumbnail Image

CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Checkpoint-Inhibitor Refractory Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint-Inhibitor Refractory Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Chemotherapy-Induced Hearing Loss - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy-Induced Hearing Loss - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
T-Cell Prolymphocytic Leukemia (T-PLL) - Pipeline Insight, 2024 - Product Thumbnail Image

T-Cell Prolymphocytic Leukemia (T-PLL) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024 - Product Thumbnail Image

Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2024 - Product Thumbnail Image

Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more